Table 1

Demographic and clinical characteristics of patients with at least 24 months of follow-up for multidrug resistant (MDR) TB treatment

CharacteristicsN=612
Age, median (IQR)27 (22–36)
Female, n (%)287 (46.9)
Previously treated603 (98.5)
Previous treatments, median (IQR)2 (2–3)
Confirmed MDR, n (%)551 (90.0)
Extrapulmonary disease, n (%)44 (7.0)
Cavitary lesions on radiograph, n (%)306/475 (64.4)
BMI, median (IQR) (n=521)16.6 (14.8–19.1)
Haemoglobin (g/dL), median (IQR) (n=555)12.7 (10.8–14.4)
Cor pulmonale, n (%)32 (5.2)
Diabetes, n (%)33 (5.4)
Tobacco smoker, n (%)67/576 (11.6)
Drug use, n (%)37 (6.0)
HIV infected, n (%)133 (21.7)
CD4 count, median cells/m3 (IQR) (n=69)239 (143–358)
Resistance*
 RIF monoresistance, n (%)2/355 (0.6)
 Resistance to INH and RIF only, n (%)28/355 (7.9)
 Resistance to INH, RIF, EMB, SM, n (%)242/355 (68.2)
  • *Among individuals with phenotypic drug-susceptibility testing performed; remaining participants had molecular resistance testing for INH and RIF only by line probe assay.

  • BMI, body mass index; EMB, ethambutol; INH, isoniazid; MDR, multidrug-resistant; RIF, rifampin; SM, streptomycin.